- NorthStar has confirmed routine weekly production of non-carrier-added Actinium-225 using electron-accelerator technology at its Beloit campus.
- The company stated that the process delivers high radionuclidic purity and a reliable, repeatable supply to address constraints in the global Ac-225 supply chain.
NorthStar Medical Radioisotopes has confirmed that it is routinely producing non-carrier-added Actinium-225 (n.c.a. Ac-225) using its electron-accelerator-based technology. The company said it is producing millicurie-level quantities on a weekly cycle, supporting both clinical development and commercial clinical programmes.
The isotope is manufactured at NorthStar’s Beloit campus. According to the company, the n.c.a. Ac-225 produced demonstrates high radionuclidic purity, which supports downstream drug product radiolabelling and therapeutic use. NorthStar cited its validated production process, manufacturing infrastructure, and quality controls as key to providing a repeatable supply to customers worldwide.
“Being first-to-market with routine, commercial-scale production of Ac-225 using electron-accelerator technology, demonstrates the strength of NorthStar’s innovative approach, and builds on our commitment of delivering high-quality radiopharmaceutical materials.”
Dr. Frank Scholz, President and CEO of NorthStar
Ac-225 is an alpha-emitting radioisotope used in the development of targeted radiopharmaceutical therapies. The isotope can be linked to antibodies, peptides, and small molecules, enabling localised radiation delivery to diseased cells. This makes it relevant for next-generation therapeutic development.
NorthStar said that establishing dependable production introduces a consistent and scalable supply into a market that has faced long-term constraints. The company stated that this will enable developers to advance clinical programmes from early-stage studies through regulatory approval and commercial launch.
